 | This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership that was established as a foundation in Switzerland in 1999. Its main mission is to reduce malaria in disease-endemic countries by developing and facilitating the delivery of antimalarial drugs.
MMV was launched in 1999, with initial seed funding of US$4 million from the Government of Switzerland, the Department for International Development (UK), the Government of the Netherlands, the World Bank, and the Rockefeller Foundation.
MMV is governed by a board of directors. The Chairman of MMV is Mr Alan Court. [1] MMV has a board of directors in North America, an Expert Scientific Advisory Committee which helps to identify projects, an Access & Product Management Advisory Committee and a Global Safety Board which reviews projects. [2]
MMV's project portfolio states that their goals are:
MMV started the Open Source Malaria project, [3] which encourages people to share procedures and results of open source research. [4] The Open Source Malaria, with researchers at the University of Sydney, supervised high school students at Sydney Grammar School who adapted a synthesis of Daraprim (pyrimethamine) using a less hazardous method. [5] [6]
| International | |
|---|---|
| National | |
